Merck & Co., Inc. (ETR:6MK)
70.70
-1.50 (-2.08%)
Jul 11, 2025, 5:35 PM CET
Merck & Co. Revenue
Merck & Co. had revenue of $15.53B USD in the quarter ending March 31, 2025, a decrease of -1.56%. This brings the company's revenue in the last twelve months to $63.92B, up 4.10% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.92B
Revenue Growth
+4.10%
P/S Ratio
3.03
Revenue / Employee
$852.29K
Employees
75,000
Market Cap
178.99B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.14B |
Merck KGaA | 21.32B |
Bayer Aktiengesellschaft | 46.58B |
Fresenius SE & Co. KGaA | 22.13B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.17B |
Merck & Co. News
- 1 day ago - Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap - Forbes
- 1 day ago - FDA Approves BRAVECTO QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Wallstreet:Online
- 1 day ago - FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire
- 1 day ago - SeaStar Medical's QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka - Benzinga
- 1 day ago - Merck's doravirine/islatravir under FDA review for HIV - Seeking Alpha
- 2 days ago - U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Wallstreet:Online
- 2 days ago - U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire
- 2 days ago - Verona Pharma (VRNA) Downgraded as Merck Plans $10B Acquisition | VRNA Stock News - GuruFocus